MX2023000945A - 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias. - Google Patents
55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias.Info
- Publication number
- MX2023000945A MX2023000945A MX2023000945A MX2023000945A MX2023000945A MX 2023000945 A MX2023000945 A MX 2023000945A MX 2023000945 A MX2023000945 A MX 2023000945A MX 2023000945 A MX2023000945 A MX 2023000945A MX 2023000945 A MX2023000945 A MX 2023000945A
- Authority
- MX
- Mexico
- Prior art keywords
- strain
- inflammatory diseases
- oral therapy
- histicola
- mevs
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 241000605861 Prevotella Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
En el presente documento se proporcionan métodos y composiciones farmacéuticas relacionadas con las bacterias y vesículas extracelulares microbianas (mEV) de la cepa C de Prevotella histicola que son útiles como agentes terapéuticos, por ejemplo, para tratar enfermedades inflamatorias (por ejemplo, una enfermedad neuroinflamatoria).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054597P | 2020-07-21 | 2020-07-21 | |
US202063054613P | 2020-07-21 | 2020-07-21 | |
PCT/US2021/042396 WO2022020364A1 (en) | 2020-07-21 | 2021-07-20 | Prevotella histicola strain c as an oral therapy for inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000945A true MX2023000945A (es) | 2023-03-15 |
Family
ID=77265333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000945A MX2023000945A (es) | 2020-07-21 | 2021-07-20 | 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230256032A1 (es) |
EP (1) | EP4185276A1 (es) |
JP (1) | JP2023535711A (es) |
KR (1) | KR20230048337A (es) |
CN (1) | CN116322656A (es) |
AU (1) | AU2021311624A1 (es) |
BR (1) | BR112023001121A2 (es) |
CA (1) | CA3186466A1 (es) |
CO (1) | CO2023001509A2 (es) |
MX (1) | MX2023000945A (es) |
TW (1) | TW202216180A (es) |
WO (1) | WO2022020364A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023192360A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same |
CN115414354A (zh) * | 2022-08-29 | 2022-12-02 | 西南医科大学 | 花椒毒素在制备治疗血小板减少症药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056680A2 (en) * | 2005-11-03 | 2007-05-18 | Forsyth Dental Infirmary For Children | Methods and arrays for identifying human microflora |
US8617536B2 (en) * | 2009-10-30 | 2013-12-31 | Mayo Foundation For Medical Education And Research | Prevotella histicola preparations and the treatment of autoimmune conditions |
CN105451576B (zh) * | 2013-06-03 | 2020-07-14 | 普罗普瑞弗股份公司 | 通过使用来自普雷沃氏菌属的至少一种细菌菌株治疗肥胖、代谢综合征、2型糖尿病、心血管疾病、痴呆、阿尔茨海默病和炎性肠病 |
US20200138878A1 (en) * | 2017-07-06 | 2020-05-07 | Probionase Therapies Inc. | Probiotic-based treatment of resistant chronic rhinosinusitis |
JP2020533291A (ja) | 2017-09-08 | 2020-11-19 | エヴェロ バイオサイエンシズ,インコーポレーテッド | プレボテラ(Prevotella)由来の細胞外小胞 |
WO2021025968A1 (en) * | 2019-08-02 | 2021-02-11 | Evelo Biosciences, Inc. | Methods and compositions for culturing hemoglobin-dependent bacteria |
-
2021
- 2021-07-20 MX MX2023000945A patent/MX2023000945A/es unknown
- 2021-07-20 EP EP21752442.0A patent/EP4185276A1/en active Pending
- 2021-07-20 KR KR1020237006022A patent/KR20230048337A/ko unknown
- 2021-07-20 JP JP2023504225A patent/JP2023535711A/ja active Pending
- 2021-07-20 CA CA3186466A patent/CA3186466A1/en active Pending
- 2021-07-20 CN CN202180050060.2A patent/CN116322656A/zh active Pending
- 2021-07-20 WO PCT/US2021/042396 patent/WO2022020364A1/en active Application Filing
- 2021-07-20 BR BR112023001121A patent/BR112023001121A2/pt unknown
- 2021-07-20 US US18/005,145 patent/US20230256032A1/en active Pending
- 2021-07-20 AU AU2021311624A patent/AU2021311624A1/en active Pending
- 2021-07-21 TW TW110126812A patent/TW202216180A/zh unknown
-
2023
- 2023-02-10 CO CONC2023/0001509A patent/CO2023001509A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4185276A1 (en) | 2023-05-31 |
CA3186466A1 (en) | 2022-01-27 |
TW202216180A (zh) | 2022-05-01 |
CO2023001509A2 (es) | 2023-02-27 |
BR112023001121A2 (pt) | 2023-02-14 |
KR20230048337A (ko) | 2023-04-11 |
AU2021311624A1 (en) | 2023-02-16 |
JP2023535711A (ja) | 2023-08-21 |
WO2022020364A1 (en) | 2022-01-27 |
CN116322656A (zh) | 2023-06-23 |
US20230256032A1 (en) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
MX2023000945A (es) | 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias. | |
MX2021015427A (es) | Vesiculas extracelulares microbianas procesadas. | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
MX2021009285A (es) | Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). | |
MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
EA202192553A1 (ru) | Protac, расщепляющие рецептор эстрогена | |
WO2019178487A3 (en) | Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae | |
MX2023007140A (es) | Compuestos farmaceuticos. | |
MX2010009462A (es) | Derivados de indazol. | |
MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
CO2023000114A2 (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae | |
PH12021550043A1 (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
MX2023000868A (es) | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. | |
WO2021252860A3 (en) | Compositions and methods for treating diseases and disorders using harryflintia acetispora | |
MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
MX2021011081A (es) | Derivados de nicorandil. | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
MX2023005971A (es) | Metodos y composicion para las modificaciones de kras. | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |